Germany first launched sales of medical cannabis products through pharmacies in 2017, and since that time, Germany has become the largest medical cannabis market in Europe. While sales of many products found in other markets remain prohibited in Germany, sales of medical cannabis flower are legal.
Frankfurt-based Bloomwell Group, Europe’s largest digital platform for medical cannabis-based therapies, recently surveyed more than 2,500 current medical cannabis patients in Germany. One of the main findings of the survey is that the average price of legal medical cannabis in Germany is €7.49 per gram.
“The share of very inexpensive flower (≤ €6/gram) rose in Q2 from 10% to now comprising 35% of the market.” Bloomwell also found via its survey. “Over 600 products are now available, but many physicians still hesitate to prescribe them due to complexity and a lack of training.”
Bloomwell conducted its survey after it was recently announced that Germany’s Ministry of Health released a draft amendment to the nation’s medical cannabis law that would prohibit medical cannabis telemedicine services in the European country. The Bloomwell survey also determined the following:
- 41.7% of patients would revert to the illegal market if digital access were blocked.
- Only 7% would consider joining one of Germany’s legal cannabis clubs, which mainly serve recreational users.
- 79% of patients previously relied on unlicensed sources (illegal market and/or through friends and acquaintances) before accessing digital therapy.
- 47.5% now say cannabis obtained from pharmacies is less expensive than unlicensed products, debunking myths about affordability. Only 13.8% responded that pharmacy cannabis is more expensive.
- 83% believe medical cannabis from pharmacies is of higher quality than illicit alternatives.
“The report also concludes that the significant price drop in Q2 suggests that Germany is approaching an oversupply of imported cannabis flower—if it hasn’t already entered that phase. This comes as Germany set a new record high for cannabis imports for medical and scientific purposes in the first quarter of 2025, with imports reaching 37 tonnes, surpassing the previous record of 32 tonnes in Q4 of 2024, according to the Federal Institute for Drugs and Medical Devices (BfArM).” Bloomwell stated in a press release provided to Cannabis Industry Data.
“Additionally, Bloomwell found that medical cannabis patient numbers show no signs of slowing down: in May and June 2025, the number of prescriptions filled on their digital platform exceeded those from March 2024—the final month before medical cannabis was reclassified—by approximately 1100%, a new record high.” the press release also stated.
Bloomwell conducted an anonymous survey in June 2025 with 2,571 patients who began cannabis therapy through Bloomwell.